Einstieg nach Kursdesaster

Coherus Announces FDA Approval of UDENYCA ONBODY, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv  

Die Neuigkeiten sind top
Denke mit gute Q4 Ergebnisse wird schnell über 10 dollar klettern  
 

Zulassung könnten wir zum Ende des Jahres 2024 den Breakeven erreichen.    

..sell on good news.  

Moin, jetzt können die offenen Gap`s nach oben abgearbeitet werden;) siehe #167
Das Volumen im Premarket ist aussagekräftig;) Lg  

nach einer Verdoppelung innerhalb ein paar Tage hin  

hätte nichts gegen eine Verdopplung bis zum neuen Jahr.  

Wahnsinns volumen heute..
Volume    52,172,830
https://finance.yahoo.com/quote/CHRS?p=CHRS

CHRS Short Interest
Settlement Date    Short Interest    Avg. Daily Share Volume    Days to Cover
11/30/2023            21,463,711            3,710,650                         5.784353
11/15/2023            21,686,625           7,409,096                          2.927027
https://www.nasdaq.com/market-activity/stocks/chrs/short-interest

 

Coherus BioSciences: A drugmaker with a 501% upside potential

Coherus BioSciences is a biopharmaceutical company that focuses on two areas: biosimilars and immuno-oncology. The company has three biosimilars on the market: Udenyca, a Neulasta biosimilar; Cimerli, a Lucentis biosimilar; and Yusimry, a Humira biosimilar. Moreover, the company recently won FDA approval for its immuno-oncology drug, Loqtorzi, as a treatment for advanced nasopharyngeal carcinoma. Coherus plans to launch Loqtorzi in the first quarter of 2024.

Despite its growing product portfolio, Coherus' stock has still plummeted by 74% this year. The main issue is the company's unfavorable cash situation. Coherus has less than a year of cash left at its current burn rate. Now, management has pledged to reduce expenses to move the company back to profitability. But investors appear to be waiting for hard evidence that this plan will bear fruit.

https://finance.yahoo.com/news/2-small-cap-stocks-could-144500653.html

 

 Analyst
$11.57

Based on analysts offering 12 month price targets for CHRS in the last 3 months. The average price target is $11.57 with a high estimate of $15 and a low estimate of $7.
https://www.nasdaq.com/market-activity/stocks/chrs/analyst-research

 

 

 

 

Beeindruckendes Handelsvolumen, allerdings bei einer Marktkapitalisierung von 240 Mio handelt es sich hier doch um ein sehr kleines Pharmaunternehmen. Ist hier nicht eher die Wahrscheinlichkeit, dass dieses Unternehmen aufgekauft wird?  

ein schöner Jahresabschluss

https://www.nasdaq.com/market-activity/stocks/chrs/analyst-research  

Das würde für mich auch einen nachzhaltigen aufwärtstrend signalisieren und ggf. „Glücksritter“ rauskegeln. Mal schauen…so bleibt es zunächst äußerst spekulativ. Ich weiß, es gibt wohl einige Analysten, die hier bis 12 Dollar sehen…Analysten eben ;-)
Gewinnmitnahmen würden mich allerdings heute leider auch nicht wundern.  

Weiß jmd. Mehr?  

Heute ist der letzte Handelstag 2023, da schließt die Börse in DE um 14 Uhr.  

 

Bei mir gibts halt keine Feiertage :-)  

December 28, 2023
Year in Review: Top Deals in 2023

    Coherus Agrees to Acquire a Biosimilar EYLEA Candidate from Klinge Biopharma

In January, Coherus BioSciences, Inc. (“Coherus”) announced the execution of a binding term sheet with Klinge Biopharma GmbH (“Klinge Biopharma”) for the exclusive commercialization rights to FYB203, Formycon AG’s (“Formycon”) biosimilar candidate to EYLEA (aflibercept), in the United States. Under the binding term sheet, Coherus will make a total upfront payment to Klinge of approximately €30 million, comprised of cash and Coherus common stock, thirty days after the execution of the definitive agreements. Coherus will also make other regulatory and launch milestone payments and share profits approximately equally with Klinge in consideration for the commercialization rights to FYB203 in the United States. Formycon AG is entitled to participate in all Klinge income under the agreement with Coherus in the mid-single to low-double-digit-percentage range. Coherus intends to launch the product at EYLEA biosimilar market formation, currently expected to be in 2025, if approved.

https://www.jdsupra.com/legalnews/...eview-top-deals-in-2023-7817564/

 

Coherus Announces U.S. Launch of LOQTORZI

Coherus BioSciences, Inc.
Tue, January 2, 2024 at 2:29

Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy

Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or after platinum containing chemotherapy, irrespective of PD-L1 status 

LOQTORZI is now available for purchase through select specialty distributors

https://finance.yahoo.com/news/...es-u-launch-loqtorzi-132900760.html

 

LOQTORZI is the first FDA-approved therapy for NPC and will represent a new standard of care for treating the disease when used in combination with cisplatin and gemcitabine in the first line setting or as monotherapy in the second line or greater setting.

https://www.finanznachrichten.de/...es-u-s-launch-of-loqtorzi-399.htm

 

Rebound in anmarsch...
xx $ price target!
Revenue in 2023---$256 Million
Revenue in 2024---$434 Million !!!!  

Coherus steigt nach Einführung der Kehlkopfkrebs-Therapie

2. Jan. 202416:50 MEZ


https://de.tradingview.com/news/reuters.com,2024:newsml_L8N3DS3J4:0/